CytomX Therapeutics, Inc. (FRA:6C1)
Germany · Delayed Price · Currency is EUR 3.604
+0.032 (0.90%)
At close: Dec 1, 2025
CytomX Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Cash & Equivalents | 34.19 | 38.05 | 17.17 | 193.65 | 205.53 | 191.86 | Upgrade |
Short-Term Investments | 109.44 | 62.57 | 157.34 | - | 99.7 | 124.26 | Upgrade |
Cash & Short-Term Investments | 143.63 | 100.62 | 174.51 | 193.65 | 305.23 | 316.12 | Upgrade |
Cash Growth | 22.14% | -42.34% | -9.88% | -36.55% | -3.45% | 6.74% | Upgrade |
Receivables | 1.63 | 3.1 | 3.43 | 35.99 | 0.79 | 0.8 | Upgrade |
Prepaid Expenses | 3.96 | 3.58 | 5 | 7.47 | 4.29 | 7.1 | Upgrade |
Total Current Assets | 149.22 | 107.31 | 182.94 | 237.1 | 310.3 | 324.01 | Upgrade |
Property, Plant & Equipment | 6.54 | 10.6 | 16.18 | 21.02 | 25.32 | 29.45 | Upgrade |
Goodwill | 0.95 | 0.95 | 0.95 | 0.95 | 0.95 | 0.95 | Upgrade |
Other Intangible Assets | 0.47 | 0.58 | 0.73 | 0.88 | 1.02 | 1.17 | Upgrade |
Other Long-Term Assets | 1.08 | 1.09 | 1 | 0.94 | 1.82 | 3.09 | Upgrade |
Total Assets | 158.25 | 120.53 | 201.79 | 260.89 | 339.41 | 358.66 | Upgrade |
Accounts Payable | 0.65 | 1.09 | 1.46 | 2.81 | 2.82 | 3 | Upgrade |
Accrued Expenses | 12.32 | 12.34 | 17.6 | 22.82 | 30.62 | 19.86 | Upgrade |
Current Portion of Leases | 5.6 | 5.15 | 4.59 | 4.08 | 3.62 | 3.2 | Upgrade |
Current Unearned Revenue | 22.38 | 67.2 | 132.27 | 121.27 | 40.82 | 42.06 | Upgrade |
Other Current Liabilities | 0.09 | - | - | 1.63 | - | - | Upgrade |
Total Current Liabilities | 41.03 | 85.77 | 155.91 | 152.61 | 77.87 | 68.11 | Upgrade |
Long-Term Leases | - | 4.24 | 9.39 | 13.98 | 18.06 | 21.68 | Upgrade |
Long-Term Unearned Revenue | 5.54 | 26.86 | 80.05 | 180.06 | 243.94 | 276.65 | Upgrade |
Other Long-Term Liabilities | 4.3 | 4.12 | 3.89 | - | - | - | Upgrade |
Total Liabilities | 50.87 | 120.99 | 249.24 | 346.64 | 339.87 | 366.44 | Upgrade |
Common Stock | 0 | 0 | 0 | 0 | 0 | 0 | Upgrade |
Additional Paid-In Capital | 789.72 | 691.1 | 675.91 | 637.12 | 623.34 | 499.96 | Upgrade |
Retained Earnings | -682.44 | -691.58 | -723.45 | -722.88 | -623.56 | -507.69 | Upgrade |
Comprehensive Income & Other | 0.1 | 0.03 | 0.1 | 0.01 | -0.24 | -0.05 | Upgrade |
Total Common Equity | 107.39 | -0.46 | -47.45 | -85.75 | -0.46 | -7.77 | Upgrade |
Shareholders' Equity | 107.39 | -0.46 | -47.45 | -85.75 | -0.46 | -7.77 | Upgrade |
Total Liabilities & Equity | 158.25 | 120.53 | 201.79 | 260.89 | 339.41 | 358.66 | Upgrade |
Total Debt | 5.6 | 9.39 | 13.97 | 18.06 | 21.67 | 24.87 | Upgrade |
Net Cash (Debt) | 138.03 | 91.24 | 160.54 | 175.59 | 283.55 | 291.25 | Upgrade |
Net Cash Growth | 29.01% | -43.17% | -8.58% | -38.07% | -2.64% | 8.49% | Upgrade |
Net Cash Per Share | 1.17 | 1.08 | 2.18 | 2.67 | 4.42 | 6.31 | Upgrade |
Filing Date Shares Outstanding | 169.44 | 80.1 | 67.72 | 66.23 | 65.39 | 64.78 | Upgrade |
Total Common Shares Outstanding | 165.07 | 80.1 | 67.31 | 66.23 | 65.39 | 48.25 | Upgrade |
Working Capital | 108.19 | 21.53 | 27.02 | 84.49 | 232.43 | 255.9 | Upgrade |
Book Value Per Share | 0.65 | -0.01 | -0.70 | -1.29 | -0.01 | -0.16 | Upgrade |
Tangible Book Value | 105.97 | -1.99 | -49.13 | -87.58 | -2.43 | -9.89 | Upgrade |
Tangible Book Value Per Share | 0.64 | -0.02 | -0.73 | -1.32 | -0.04 | -0.20 | Upgrade |
Machinery | - | 16.69 | 16.3 | 17 | 17.75 | 16.4 | Upgrade |
Construction In Progress | - | - | 0.37 | 0.71 | 0.31 | 0.25 | Upgrade |
Leasehold Improvements | - | 2.01 | 1.98 | 1.74 | 1.74 | 1.73 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.